

September 14, 2017



# Aethlon Medical Receives National Cancer Institute Contract Award

SAN DIEGO, Sept. 14, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the National Cancer Institute (NCI) has awarded the Company a government contract (number HHSN261201700022C). The title of this SBIR Topic 359 Phase I contract is "Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes."

The NCI Phase I contract period runs from September 15, 2017 and runs through June 14, 2018. The total amount of the firm fixed price contract is \$299,250. The contract calls for two subcontractors to work with the Company. The subcontractors under Aethlon Medical on the contract are University of Pittsburgh and Massachusetts General Hospital.

Aethlon Medical is investigating the potential use of the Aethlon Hemopurifier® to reduce the presence of circulating tumor-derived exosomes (oncosomes), which contribute to cancer progression. The Hemopurifier® is currently being advanced to treat life-threatening viral infections under an FDA designated Expedited Access Pathway (EAP) program. The Company is also engaged in the advancement of exosomal biomarkers to diagnose and monitor cancer and other disease conditions.

## About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® was designed to reduce the presence of life-threatening viral pathogens from the circulatory system of infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with approved therapies, including a broad-spectrum of naturally occurring pandemic threats and agents of bioterrorism. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Aethlon Medical is the majority owner of Exosome Sciences, Inc. (ESI), which is a diagnostic company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). Additional information can be found online at [www.AethlonMedical.com](http://www.AethlonMedical.com) and [www.ExosomeSciences.com](http://www.ExosomeSciences.com). You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

## Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe,"

"anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2017, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

**Company Contact:**

Jim Frakes  
Chief Financial Officer  
Aethlon Medical, Inc.  
858-489-7800 x3300  
[Jfrakes@aethlonmedical.com](mailto:Jfrakes@aethlonmedical.com)

**Media Contact:**

David Schull or Maggie Beller  
Russo Partners, LLC  
[David.Schull@RussoPartnersLLC.com](mailto:David.Schull@RussoPartnersLLC.com)  
[Maggie.Beller@RussoPartnersLLC.com](mailto:Maggie.Beller@RussoPartnersLLC.com)  
212-845-4271

**Investor Relations:**

John Marco  
CORE IR  
516 222 2560  
[johnm@coreir.com](mailto:johnm@coreir.com)

View original content:<http://www.prnewswire.com/news-releases/aethlon-medical-receives-national-cancer-institute-contract-award-300519147.html>

SOURCE Aethlon Medical, Inc.